Immunocore(IMCR) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 160 mcg selected as the go-forward dose for brenetafusp in Phase 3 PRISM-MEL-301 trial, following Independent Data Monitoring Committee review Cash, cash equivalents and marketable securities of $892 million as of September 30, 2025 (OXFORDSHIRE, Eng ...